Assessment of Capsule Endoscopy Utilizing Capsocam Plus in Patients With Suspected Small Bowel Disease Including Pilot Study With Remote Access Patients During Pandemic
Journal of the Canadian Association of Gastroenterology · 03.12.2021 · 4 (6) · 269-273
DOI: 10.1093/jcag/gwaa042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Canadian Association of Gastroenterology, online erschienen am 09.01.2021. Verfasst von Chasyn Enns und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
CapsoCam Plus is a capsule endoscopy (CE) system that utilizes four cameras to capture a panoramic view. This has theoretical advantage over conventional forward-viewing CE with limited field of view. Its ease of administration without requiring any additional equipment during the recording also provides a unique opportunity for patients to self-administer the test. We aimed to evaluate real-life experience using this novel system and to determine feasibility of a remote access program.
Methods
Retrospective chart review was conducted for consecutive adult outpatients who underwent CE using CapsoCam Plus. Patients with significant challenges for in-person procedures were selected for remote access through mail courier services. Gastric transit time, small bowel transit time, completion rate, diagnostic yield and adverse events were compared between remote access versus usual practice.
Results
Ninety-four patients (52.1% male) were included, with 28 in remote access program. Most common indication was gastrointestinal bleeding (85.1%). Complete examination was achieved in 87 patients. Five (5.3%) patients’ capsule remained in stomach during the recording, while two (2.1%) patients missed capsule retrieval. Median small bowel and gastric transit times were 231.9 (interquartile range [IQR] 169.5–308.2) and 27.6 (IQR 13.8–63.5) minutes, respectively. Diagnostic yield was 23.4%. There was no difference in completion rate or transit times between two groups, but diagnostic yield was higher in remote access group (odds ratio 3.80, 95% confidence interval 1.28–11.31). One patient required elective endoscopic retrieval of capsule.
Conclusion
CapsoCam Plus can be safely administered remotely with a high degree of success, which may facilitate timely investigations while limiting nonessential physical interactions during pandemic.
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Zitieren
APA
Enns, C., Galorport, C., Ou, G., & Enns, R. (2021). Assessment of Capsule Endoscopy Utilizing Capsocam Plus in Patients With Suspected Small Bowel Disease Including Pilot Study With Remote Access Patients During Pandemic. Journal of the Canadian Association of Gastroenterology, 4(6), 269-273. https://doi.org/10.1093/jcag/gwaa042
Vancouver
Enns C, Galorport C, Ou G, Enns R. Assessment of Capsule Endoscopy Utilizing Capsocam Plus in Patients With Suspected Small Bowel Disease Including Pilot Study With Remote Access Patients During Pandemic. Journal of the Canadian Association of Gastroenterology. 2021;4(6):269-273. doi:10.1093/jcag/gwaa042
BibTeX
@article{Enns2021,
author = {Enns, Chasyn and Galorport, Cherry and Ou, George and Enns, Robert},
title = {Assessment of Capsule Endoscopy Utilizing Capsocam Plus in Patients With Suspected Small Bowel Disease Including Pilot Study With Remote Access Patients During Pandemic},
journal = {Journal of the Canadian Association of Gastroenterology},
year = {2021},
volume = {4},
number = {6},
pages = {269--273},
doi = {10.1093/jcag/gwaa042}
}
EUVIMED